Safety, efficacy, and pharmacodynamics of the investigational agent TAK-700 in metastatic castration-resistant prostate cancer (mCRPC): Updated data from a phase I/II study.
D. B. Agus
Consultant or Advisory Role - Takeda
W. M. Stadler
Consultant or Advisory Role - Takeda
D. H. Shevrin
No relevant relationships to disclose
L. Hart
Research Funding - Millennium
G. R. MacVicar
No relevant relationships to disclose
O. Hamid
Consultant or Advisory Role - Millennium
Research Funding - Millennium
J. D. Hainsworth
No relevant relationships to disclose
M. E. Gross
No relevant relationships to disclose
J. Wang
Employment or Leadership Position - Millennium
L. de Leon
Employment or Leadership Position - Millennium
Stock Ownership - Millennium
D. MacLean
Employment or Leadership Position - Millennium
R. Dreicer
Consultant or Advisory Role - Millennium
Honoraria - Millennium